We hear this a lot but most patients are surprised by how simple the weekly injection is
Oral versions of GLP-1s have also been approved, though they thus far have lower efficacy
A malnourished mother on any weight loss medication, GLP-1 or otherwise, poses significant risk
Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health
These medications differ from other weight loss treatments like orlistat or phentermine
In May, the MHRA and the ASA published an Enforcement Notice which makes clear to businesses which offer vitamin shots the nature of the rulings and directs them to remove any COVID-19 related claims from their websites and social media pages